These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24569777)

  • 1. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
    Stübig T; Alchalby H; Ditschkowski M; Wolf D; Wulf G; Zabelina T; Wolschke C; Ayuk F; Kröger N
    Leukemia; 2014 Aug; 28(8):1736-8. PubMed ID: 24569777
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.
    Pu JJ; Poulose J; Malysz J; Zhu J; Fanburg-Smith JC; Claxton DF; Bayerl MG
    Br J Haematol; 2019 Sep; 186(5):e130-e133. PubMed ID: 31115038
    [No Abstract]   [Full Text] [Related]  

  • 3. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
    Lee SC; Feenstra J; Georghiou PR
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24891492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem-cell transplantation for myelofibrosis.
    Lavi N; Rowe JM; Zuckerman T
    Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
    Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib: the first agent approved for myelofibrosis.
    Verstovsek S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
    Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
    Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib (Jakafi) for myelofibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
    Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U
    Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334
    [No Abstract]   [Full Text] [Related]  

  • 13. Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
    Pardanani A
    Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996
    [No Abstract]   [Full Text] [Related]  

  • 14. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 18. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
    Geyer H; Cannon K; Knight E; Fauble V; Camoriano J; Emanuel R; Tibes R; Mesa R
    Leuk Lymphoma; 2014 Jan; 55(1):195-7. PubMed ID: 23647081
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib.
    Mesa RA; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Feb; 11(2):103-4. PubMed ID: 22293561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.